Open AccessInflammation, Statin Therapy, and Risk of Stroke After an Acute Coronary Syndrome in the MIRACL Study
Author(s) -
Scott Kinlay,
Gregory G. Schwartz,
Anders Olsson,
Nader Rifai,
Michael Szarek,
David D. Waters,
Peter Libby,
Peter Ganz
Publication year - 2007
Publication title -
arteriosclerosis thrombosis and vascular biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.007
H-Index - 270
eISSN - 1524-4636
pISSN - 1079-5642
DOI - 10.1161/atvbaha.107.151787
Subject(s) - medicine , atorvastatin , acute coronary syndrome , c reactive protein , stroke (engine) , inflammation , placebo , quartile , statin , gastroenterology , cardiology , systemic inflammation , interleukin 6 , serum amyloid a , myocardial infarction , pathology , confidence interval , mechanical engineering , alternative medicine , engineering
Patients with acute coronary syndromes have an increased risk of stroke. We measured markers of inflammation in the MIRACL study, a randomized trial of atorvastatin versus placebo in acute coronary syndromes, to assess the relationship of inflammation to stroke.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom